Inactive Instrument

Highlights Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Acquisition Deal	23-08-14	MT
Harmony Biosciences Agrees to Acquire Zynerba Pharmaceuticals	23-08-14	MT
Harmony Biosciences To Acquire Zynerba Pharmaceuticals, Inc.	23-08-14	RE
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Harmony Biosciences Holdings, Inc. entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ) for $63.7 million.	23-08-13	CI
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Zynerba Pharmaceuticals, Inc. Presents Data on Zygel at the 55th Gatlinburg Conference	23-04-12	CI
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-28	CI
Optimism Ahead of Consumer Confidence Report Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	22-12-21	MT
Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome	22-12-21	CI
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology	22-12-05	CI
Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders	22-11-28	CI
Zynerba's 22q11.2 Deletion Syndrome Treatment Receives European Orphan Drug Designation	22-11-15	MT
Zynerba Pharmaceuticals Announces European Commission has Granted Orphan Drug Designation for Zygel(Tm) in 22Q11.2 Deletion Syndrome	22-11-15	CI
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Earnings Flash (ZYNE) ZYNERBA PHARMACEUTICALS Posts Q3 Loss $-0.20	22-11-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Highlights

Filters